Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK)
HKD 4.46
(0.22%)
HKD 4.46
(0.22%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 3.71 Billion CNY | -14.19% |
| 2022 | 4.32 Billion CNY | 59.6% |
| 2021 | 2.7 Billion CNY | -7.59% |
| 2020 | 2.93 Billion CNY | -41.57% |
| 2019 | 5.01 Billion CNY | 79.61% |
| 2018 | 2.79 Billion CNY | 130.96% |
| 2017 | 1.2 Billion CNY | 282.53% |
| 2016 | -662.78 Million CNY | 61.83% |
| 2015 | -1.73 Billion CNY | 44.31% |
| 2014 | -3.11 Billion CNY | 48.46% |
| 2013 | -6.05 Billion CNY | 7.14% |
| 2012 | -6.51 Billion CNY | 3.82% |
| 2011 | -6.77 Billion CNY | -8.23% |
| 2010 | -6.25 Billion CNY | -3007.93% |
| 2009 | -201.37 Million CNY | -640.0% |
| 2008 | 37.29 Million CNY | -22.31% |
| 2007 | 48 Million CNY | -27.25% |
| 2006 | 65.97 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 2.26 Billion CNY | -68.21% |
| 2024 Q1 | 2.71 Billion CNY | -26.71% |
| 2023 Q4 | 3.71 Billion CNY | -9.92% |
| 2023 FY | 3.71 Billion CNY | -14.19% |
| 2023 Q1 | 3.72 Billion CNY | -13.88% |
| 2023 Q2 | 3.94 Billion CNY | 5.81% |
| 2023 Q3 | 4.11 Billion CNY | 4.53% |
| 2022 Q3 | 4.04 Billion CNY | 12.92% |
| 2022 FY | 4.32 Billion CNY | 59.6% |
| 2022 Q1 | 2.86 Billion CNY | 5.8% |
| 2022 Q4 | 4.32 Billion CNY | 7.01% |
| 2022 Q2 | 3.57 Billion CNY | 24.85% |
| 2021 Q3 | 1.77 Billion CNY | 1.89% |
| 2021 Q1 | 2.51 Billion CNY | -14.15% |
| 2021 Q2 | 1.74 Billion CNY | -30.74% |
| 2021 FY | 2.7 Billion CNY | -7.59% |
| 2021 Q4 | 2.7 Billion CNY | 52.53% |
| 2020 FY | 2.93 Billion CNY | -41.57% |
| 2020 Q3 | 2.71 Billion CNY | -51.16% |
| 2020 Q4 | 2.93 Billion CNY | 8.13% |
| 2020 Q2 | 5.55 Billion CNY | 1.51% |
| 2020 Q1 | 5.46 Billion CNY | 8.99% |
| 2019 Q3 | 5 Billion CNY | 11.09% |
| 2019 Q4 | 5.01 Billion CNY | 0.25% |
| 2019 Q1 | 2.92 Billion CNY | 4.74% |
| 2019 Q2 | 4.5 Billion CNY | 53.98% |
| 2019 FY | 5.01 Billion CNY | 79.61% |
| 2018 Q4 | 2.79 Billion CNY | 1.22% |
| 2018 FY | 2.79 Billion CNY | 130.96% |
| 2018 Q3 | 2.76 Billion CNY | 8.47% |
| 2018 Q2 | 2.54 Billion CNY | 104.51% |
| 2018 Q1 | 1.24 Billion CNY | 2.86% |
| 2017 Q4 | 1.2 Billion CNY | 166.21% |
| 2017 FY | 1.2 Billion CNY | 282.53% |
| 2017 Q3 | 454.44 Million CNY | 449.39% |
| 2017 Q2 | -130.07 Million CNY | 47.24% |
| 2017 Q1 | -246.53 Million CNY | 62.8% |
| 2016 Q1 | -1.96 Billion CNY | -12.9% |
| 2016 FY | -662.78 Million CNY | 61.83% |
| 2016 Q3 | -1.5 Billion CNY | 15.84% |
| 2016 Q4 | -662.78 Million CNY | 55.83% |
| 2016 Q2 | -1.78 Billion CNY | 9.07% |
| 2015 Q2 | -3.23 Billion CNY | 9.3% |
| 2015 Q1 | -3.56 Billion CNY | -14.26% |
| 2015 Q3 | -3.5 Billion CNY | -8.45% |
| 2015 FY | -1.73 Billion CNY | 44.31% |
| 2015 Q4 | -1.73 Billion CNY | 50.45% |
| 2014 Q3 | -3.62 Billion CNY | 10.19% |
| 2014 Q2 | -4.03 Billion CNY | 34.85% |
| 2014 Q1 | -6.19 Billion CNY | -2.39% |
| 2014 Q4 | -3.11 Billion CNY | 13.97% |
| 2014 FY | -3.11 Billion CNY | 48.46% |
| 2013 Q3 | -6.15 Billion CNY | -3.7% |
| 2013 Q4 | -6.05 Billion CNY | 1.71% |
| 2013 Q1 | -6.36 Billion CNY | 2.38% |
| 2013 FY | -6.05 Billion CNY | 7.14% |
| 2013 Q2 | -5.93 Billion CNY | 6.68% |
| 2012 FY | -6.51 Billion CNY | 3.82% |
| 2012 Q4 | -6.51 Billion CNY | 3.84% |
| 2012 Q3 | -6.77 Billion CNY | -1.38% |
| 2012 Q2 | -6.68 Billion CNY | 7.48% |
| 2012 Q1 | -7.22 Billion CNY | -6.63% |
| 2011 FY | -6.77 Billion CNY | -8.23% |
| 2011 Q2 | -6.29 Billion CNY | 4.37% |
| 2011 Q3 | -6.89 Billion CNY | -9.52% |
| 2011 Q4 | -6.77 Billion CNY | 1.74% |
| 2011 Q1 | -6.58 Billion CNY | -5.18% |
| 2010 Q1 | -150.53 Million CNY | 25.25% |
| 2010 FY | -6.25 Billion CNY | -3007.93% |
| 2010 Q4 | -6.25 Billion CNY | -5.82% |
| 2010 Q3 | -5.91 Billion CNY | -5.4% |
| 2010 Q2 | -5.61 Billion CNY | -3627.61% |
| 2009 FY | -201.37 Million CNY | -640.0% |
| 2009 Q2 | -241.05 Million CNY | 0.0% |
| 2009 Q4 | -201.37 Million CNY | 0.0% |
| 2008 FY | 37.29 Million CNY | -22.31% |
| 2007 FY | 48 Million CNY | -27.25% |
| 2006 FY | 65.97 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | -258.7 Million HKD | 1534.531% |
| Grand Pharmaceutical Group Limited | 2.03 Billion HKD | -82.649% |
| Extrawell Pharmaceutical Holdings Limited | 5.94 Million HKD | -62335.629% |
| Wai Yuen Tong Medicine Holdings Limited | 301.53 Million HKD | -1130.756% |
| Qianhai Health Holdings Limited | -19.03 Million HKD | 19593.507% |
| Lee's Pharmaceutical Holdings Limited | 30.94 Million HKD | -11891.643% |
| Essex Bio-Technology Limited | -219.22 Million HKD | 1792.83% |
| Tongfang Kontafarma Holdings Limited | 256.16 Million HKD | -1348.749% |
| PuraPharm Corporation Limited | 377.54 Million HKD | -882.965% |
| SSY Group Limited | 1.71 Billion HKD | -116.581% |
| JBM (Healthcare) Limited | -7.39 Million HKD | 50257.776% |
| Jacobson Pharma Corporation Limited | 337.44 Million HKD | -999.796% |
| China Resources Pharmaceutical Group Limited | 50.97 Billion HKD | 92.72% |